Biomarkers for Parkison's disease: Tools to assess Parkinson's disease onset and progression
Identifieur interne : 000E56 ( Main/Exploration ); précédent : 000E55; suivant : 000E57Biomarkers for Parkison's disease: Tools to assess Parkinson's disease onset and progression
Auteurs : Kenneth Marek [États-Unis] ; Danna Jennings [États-Unis] ; Gilles Tamagnan [États-Unis] ; John Seibyl [États-Unis]Source :
- Annals of Neurology [ 0364-5134 ] ; 2008-12.
Abstract
Reliable and well‐validated biomarkers for PD to identify individuals “at risk” before motor symptoms, accurately diagnose individuals at the threshold of clinical PD, and monitor PD progression throughout its course would dramatically accelerate research into both PD cause and therapeutics. Biomarkers offer the potential to provide a window onto disease mechanism, potentially generating therapeutic targets for disease. In particular, biomarkers enable investigation of the premotor period of PD before typical symptoms are manifest, but while degeneration has already begun. Given the multiple genetic causes for PD already identified, the marked variability in the loss of dopaminergic markers measured by imaging at motor symptom onset and the clear heterogeneity of clinical symptoms in PD onset and clinical progression, it is likely many biomarkers with a focus ranging from clinical symptoms to PD pathobiology to molecular genetic mechanisms will be necessary to fully map PD risk and progression. Biomarkers are also critical in new drug development for PD, both in early validation studies to assess drug dosing and to determine drug penetrance into the brain, and in later efficacy studies to complement PD clinical outcomes. During the past two decades, much progress has been made in identifying and assessing PD biomarkers, but as yet, no fully validated biomarker for PD is currently available. Nonetheless, there is increasing evidence that molecular genetics, focused ‐omic (proteomic, metabolomic, and transcriptomic) assessment of blood and cerebrospinal fluid, and advanced in vivo brain imaging will provide critical clues to assist in the diagnosis and medical management of PD patients. Ann Neurol 2008;64 (suppl):S111–S121
Url:
DOI: 10.1002/ana.21602
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Biomarkers for Parkison's disease: Tools to assess Parkinson's disease onset and progression</title><author><name sortKey="Marek, Kenneth" sort="Marek, Kenneth" uniqKey="Marek K" first="Kenneth" last="Marek">Kenneth Marek</name></author><author><name sortKey="Jennings, Danna" sort="Jennings, Danna" uniqKey="Jennings D" first="Danna" last="Jennings">Danna Jennings</name></author><author><name sortKey="Tamagnan, Gilles" sort="Tamagnan, Gilles" uniqKey="Tamagnan G" first="Gilles" last="Tamagnan">Gilles Tamagnan</name></author><author><name sortKey="Seibyl, John" sort="Seibyl, John" uniqKey="Seibyl J" first="John" last="Seibyl">John Seibyl</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0EEFB35A16B0C4B53498468A4125CA19E9BC5EC2</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/ana.21602</idno><idno type="url">https://api.istex.fr/document/0EEFB35A16B0C4B53498468A4125CA19E9BC5EC2/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000108</idno><idno type="wicri:Area/Main/Curation">000087</idno><idno type="wicri:Area/Main/Exploration">000E56</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Biomarkers for Parkison's disease: Tools to assess Parkinson's disease onset and progression</title><author><name sortKey="Marek, Kenneth" sort="Marek, Kenneth" uniqKey="Marek K" first="Kenneth" last="Marek">Kenneth Marek</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Institute for Neurodegenerative Disorders, New Haven</wicri:cityArea></affiliation></author><author><name sortKey="Jennings, Danna" sort="Jennings, Danna" uniqKey="Jennings D" first="Danna" last="Jennings">Danna Jennings</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Institute for Neurodegenerative Disorders, New Haven</wicri:cityArea></affiliation></author><author><name sortKey="Tamagnan, Gilles" sort="Tamagnan, Gilles" uniqKey="Tamagnan G" first="Gilles" last="Tamagnan">Gilles Tamagnan</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Institute for Neurodegenerative Disorders, New Haven</wicri:cityArea></affiliation></author><author><name sortKey="Seibyl, John" sort="Seibyl, John" uniqKey="Seibyl J" first="John" last="Seibyl">John Seibyl</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Institute for Neurodegenerative Disorders, New Haven</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-12">2008-12</date><biblScope unit="volume">64</biblScope><biblScope unit="issue">S2</biblScope><biblScope unit="supplement">2</biblScope><biblScope unit="page" from="S111">S111</biblScope><biblScope unit="page" to="S121">S121</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">0EEFB35A16B0C4B53498468A4125CA19E9BC5EC2</idno><idno type="DOI">10.1002/ana.21602</idno><idno type="ArticleID">ANA21602</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Reliable and well‐validated biomarkers for PD to identify individuals “at risk” before motor symptoms, accurately diagnose individuals at the threshold of clinical PD, and monitor PD progression throughout its course would dramatically accelerate research into both PD cause and therapeutics. Biomarkers offer the potential to provide a window onto disease mechanism, potentially generating therapeutic targets for disease. In particular, biomarkers enable investigation of the premotor period of PD before typical symptoms are manifest, but while degeneration has already begun. Given the multiple genetic causes for PD already identified, the marked variability in the loss of dopaminergic markers measured by imaging at motor symptom onset and the clear heterogeneity of clinical symptoms in PD onset and clinical progression, it is likely many biomarkers with a focus ranging from clinical symptoms to PD pathobiology to molecular genetic mechanisms will be necessary to fully map PD risk and progression. Biomarkers are also critical in new drug development for PD, both in early validation studies to assess drug dosing and to determine drug penetrance into the brain, and in later efficacy studies to complement PD clinical outcomes. During the past two decades, much progress has been made in identifying and assessing PD biomarkers, but as yet, no fully validated biomarker for PD is currently available. Nonetheless, there is increasing evidence that molecular genetics, focused ‐omic (proteomic, metabolomic, and transcriptomic) assessment of blood and cerebrospinal fluid, and advanced in vivo brain imaging will provide critical clues to assist in the diagnosis and medical management of PD patients. Ann Neurol 2008;64 (suppl):S111–S121</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Connecticut</li></region></list><tree><country name="États-Unis"><region name="Connecticut"><name sortKey="Marek, Kenneth" sort="Marek, Kenneth" uniqKey="Marek K" first="Kenneth" last="Marek">Kenneth Marek</name></region><name sortKey="Jennings, Danna" sort="Jennings, Danna" uniqKey="Jennings D" first="Danna" last="Jennings">Danna Jennings</name><name sortKey="Seibyl, John" sort="Seibyl, John" uniqKey="Seibyl J" first="John" last="Seibyl">John Seibyl</name><name sortKey="Tamagnan, Gilles" sort="Tamagnan, Gilles" uniqKey="Tamagnan G" first="Gilles" last="Tamagnan">Gilles Tamagnan</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E56 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000E56 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:0EEFB35A16B0C4B53498468A4125CA19E9BC5EC2
|texte= Biomarkers for Parkison's disease: Tools to assess Parkinson's disease onset and progression
}}
| This area was generated with Dilib version V0.6.23. |  |